Rasagiline is an oral, irreversible monoamine oxidase-B (MAO-B) inhibitor approved for symptomatic treatment of Parkinson's disease. It is used as monotherapy in early disease and as add-on treatment to levodopa in patients with motor fluctuations.[@parkinson2002][@olanow2009][@rascol2005][@parkinson2005] In NeuroWiki, rasagiline is relevant for two reasons: (1) established dopaminergic symptomatic benefit in PD, and (2) a broader neuroprotection hypothesis based on its propargylamine scaffold and mitochondrial/anti-apoptotic signaling effects.[@youdim2006][@youdim2008][@weinreb2010]
For progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), rasagiline should currently be viewed as a low-certainty adjunct for selected symptomatic targets, not a disease-modifying therapy. Evidence in atypical parkinsonism is weaker than in PD and does not show clear progression slowing.[@bensimon2009][@stamelou2017]
| Domain | Current Position |
|---|---|
| Regulatory status | Approved for PD (US/EU and other regions) |
| Typical dose | 1 mg once daily (0.5 mg in selected interactions/comorbidity settings) |
| Main evidence strength | Symptomatic PD benefit (monotherapy and adjunct) |
| Disease-modification signal | Suggestive but controversial delayed-start signal in ADAGIO |
| CBS/PSP evidence | Limited and inconclusive; no robust disease-modifying signal |
| Major practical risk | Drug-drug interactions (serotonergic/MAOI/opioid and CYP1A2 context) |
MAO-B inhibition reduces oxidative dopamine deamination and increases synaptic dopamine availability in striatal pathways.[@youdim2006][@finberg2016] Because rasagiline binds MAO-B irreversibly, pharmacodynamic inhibition outlasts plasma half-life and supports once-daily dosing.[@finberg2016][@us2017] Clinical benefit in PD motor domains is consistent with this mechanism and reproducible across pivotal studies.[@parkinson2002][@rascol2005][@parkinson2005]
Rasagiline's propargylamine group has been investigated for MAO-B-independent effects: anti-apoptotic signaling, mitochondrial membrane stabilization, and pro-survival transcriptional programs in preclinical models.[@youdim2008][@weinreb2010][@naoi2012] Proposed pathways include BCL-2 family modulation, protein kinase C-linked survival signaling, and attenuation of oxidative injury.[@youdim2008][@weinreb2010][@naoi2012] This mechanistic portfolio is biologically plausible for broad neurodegeneration, but translational certainty remains lower than for dopaminergic symptomatic effects.
CBS and classic PSP are usually 4R tauopathies with network-level degeneration in corticobasal, basal ganglia, and brainstem circuits.[@kovacs2015][@boxer2022] Rasagiline does not directly target tau aggregation/seed propagation. Any benefit would likely be indirect (mitochondrial stress buffering, oxidative stress attenuation, and limited dopaminergic support for selected motor symptoms), making large disease-modifying effects unlikely as monotherapy.[@bensimon2009][@stamelou2017][@boxer2022]
The TEMPO trial demonstrated improvement in clinical scores for early PD patients treated with rasagiline versus placebo, supporting monotherapy utility in early disease.[@parkinson2002] The study established efficacy and tolerability, and it also seeded the delayed-start disease-modification discussion later explored in ADAGIO.[@parkinson2002][@olanow2009]
In levodopa-treated patients with wearing-off, PRESTO and LARGO found reduced OFF time and improved functional periods versus placebo, positioning rasagiline as an effective add-on for fluctuation management.[@rascol2005][@parkinson2005] These effects are clinically meaningful for day-to-day function even when disease progression continues.
ADAGIO used a delayed-start design to test potential disease modification. The 1 mg/day arm met all three hierarchical endpoints, while 2 mg/day did not, creating an asymmetric signal that remains debated.[@olanow2009][@olanow2012]
Key interpretations:
Bottom line: ADAGIO supports a hypothesis of possible modification in a subgroup/dose context, but does not provide definitive proof of progression slowing at population level.[@olanow2012][@hanagasi2016]
NNIPPS is frequently cited in atypical parkinsonism discussions, but the interventional agent in NNIPPS was riluzole, not rasagiline.[@bensimon2009] Its negative outcome is still relevant as a cautionary benchmark for the difficulty of showing progression modification in PSP/MSA trials, but it cannot be used as direct efficacy evidence against rasagiline.
The PROSPERA randomized clinical trial evaluated rasagiline in PSP and did not show a significant slowing of PSP Rating Scale progression over one year.[@stamelou2017] This is the strongest direct clinical signal currently available for PSP and argues against meaningful monotherapy disease modification.
Dedicated rasagiline trials in CBS are lacking. Any use in CBS is currently extrapolative from:
Given tau-centric cortical pathology in CBS, expected effect size is likely modest and symptomatic rather than disease-modifying unless combined with tau-directed interventions.[@kovacs2015][@boxer2022]
Rasagiline is rapidly absorbed, hepatically metabolized (primarily CYP1A2), and exhibits short plasma half-life but prolonged pharmacodynamic impact due to irreversible MAO-B inhibition.[@finberg2016][@us2017][@chen2007] This supports a simple once-daily schedule and facilitates adherence.
| Clinical context | Typical approach |
|---|---|
| Early PD monotherapy | 1 mg daily |
| Adjunct to levodopa with OFF episodes | 1 mg daily |
| Strong CYP1A2 inhibition present | Consider reduced dose and closer monitoring |
| Frailty/polypharmacy | Start low and monitor orthostasis, confusion, sleep effects |
In CBS/PSP care, dosing is usually conservative and individualized, especially when dysphagia, frailty, orthostatic intolerance, or complex polypharmacy are present.
| Co-medication class | Risk mechanism | Practical action |
|---|---|---|
| Non-selective MAO inhibitors | Excess monoaminergic effect | Contraindicated |
| Meperidine, tramadol, methadone, propoxyphene | Serotonergic/toxic interaction risk | Avoid/contraindicated in label guidance |
| SSRIs/SNRIs/TCAs | Serotonin toxicity risk (low but non-zero) | Use only with careful risk review and monitoring |
| Dextromethorphan | CNS/serotonergic interaction | Avoid where possible |
| Ciprofloxacin and other CYP1A2 inhibitors | Raised rasagiline exposure | Consider dose reduction/monitoring |
| Sympathomimetics | Hypertension/adrenergic effects | Caution and BP monitoring |
Regulatory labeling and pharmacology reviews should anchor prescribing decisions in complex regimens.[@us2017][@chen2007]
At approved PD doses, rasagiline remains sufficiently MAO-B selective that strict tyramine-restricted diets are generally not required, but extreme tyramine loads and interacting drugs still warrant caution.[@elsworth1983][@de2006]
Across PD trials, rasagiline is generally well tolerated. Common adverse effects include headache, arthralgia, dyspepsia, and insomnia; when combined with levodopa, dyskinesia and orthostatic symptoms are more clinically relevant.[@parkinson2002][@rascol2005][@parkinson2005][@chen2007] Neuropsychiatric monitoring remains important in older adults with cognitive vulnerability.
For CBS/PSP populations:
| Dimension | Score (0-10) | Rationale |
|---|---|---|
| Mechanistic Clarity | 8 | Strong MAO-B target engagement plus coherent propargylamine stress-response biology |
| Clinical Evidence | 7 | Multiple RCTs/meta-analyses support PD symptomatic efficacy; PSP progression impact remains negative |
| Preclinical Evidence | 8 | Broad preclinical neuroprotection and metabolite biology across model systems |
| Replication | 7 | Symptomatic PD findings repeatedly replicated across trials, regions, and pooled analyses |
| Effect Size | 5 | Moderate symptomatic PD effect; small/uncertain effect in PSP/CBS context |
| Safety/Tolerability | 8 | Favorable at standard dosing with interaction vigilance |
| Biological Plausibility | 6 | Indirect overlap with tauopathy stress pathways, but not tau-targeted |
| Actionability | 8 | Widely available once-daily oral therapy with clear operational monitoring framework |
| Total | 60/80 | High-confidence symptomatic PD utility with pragmatic actionability; CBS/PSP progression-modification evidence remains low-confidence |
Rasagiline can be considered a second-line adjunct when clinicians are targeting parkinsonian slowness/rigidity and want a relatively simple oral option, but expectations should be calibrated:
A rational future strategy is combination development: rasagiline for dopaminergic/mitochondrial stress support plus direct tau-pathway agents, rehabilitation, and fall-prevention care bundles.[@stamelou2017][@kovacs2015][@boxer2022]
ADAGIO was designed around a three-endpoint delayed-start framework intended to reduce false attribution of pure symptomatic effects to disease modification.[@olanow2009][@olanow2012] In simplified terms, a disease-modifying interpretation needs all three conditions:
The 1 mg/day arm satisfied this structure, but the 2 mg/day arm did not.[@olanow2009] This internal discordance drives most of the controversy. Methodologic critiques emphasize:
Supportive arguments still exist:
For practical decision-making, ADAGIO is best treated as hypothesis-generating for modification and evidence-confirming for symptomatic utility. That distinction matters in CBS/PSP, where clinicians should avoid overpromising progression effects based on PD delayed-start evidence alone.[@stamelou2017][@boxer2022]
Rasagiline and selegiline are both propargylamine MAO-B inhibitors, but they differ in metabolic liabilities and tolerability framing. Selegiline generates amphetamine-like metabolites, while rasagiline's principal metabolite is 1-aminoindan, which avoids stimulant-like metabolite concerns in routine use.[@youdim2008][@weinreb2010][@chen2007]
Mechanistic implications for translational neurology:
From a CBS/PSP perspective, medicinal chemistry does not solve the central challenge: tau network degeneration is not primarily a dopamine-depletion syndrome. The drug may still offer localized symptomatic benefit in parkinsonian domains and possibly modest stress-buffering effects, but mechanistic distance from tau seeding/spread remains a major biological limitation.[@kovacs2015][@boxer2022]
In tertiary movement-disorder clinics, interaction failures are more often process errors than pharmacology ignorance. A practical rasagiline safety workflow:
This operational framing is especially important in PSP/CBS care where patients frequently cross neurology, geriatrics, palliative medicine, and rehabilitation interfaces. Small coordination failures can produce outsized adverse outcomes in frail patients with dysphagia, falls, and executive impairment.[@us2017][@boxer2022][@chen2007]
Absolute prohibitions and real-world practice are not identical. Many clinics co-prescribe selective serotonergic antidepressants with rasagiline when psychiatric burden is clinically important, but only under structured monitoring. Core safeguards include:
This is risk-managed co-prescribing, not evidence of zero interaction risk. Label guidance still carries high-importance warnings and should anchor local protocols.[@us2017][@chen2007]
Before trial:
During trial (4-8 weeks):
Stop criteria:
This approach keeps rasagiline in an evidence-consistent lane: a bounded symptomatic trial rather than presumed neuroprotection in tauopathy.[@stamelou2017][@boxer2022]
Rasagiline's strongest comparative advantages are once-daily simplicity, broad clinician familiarity, and a large PD evidence footprint. Comparative limitations include lack of compelling disease-modification proof and weak evidence in atypical parkinsonism populations.[@olanow2009][@stamelou2017][@olanow2012]
Against selegiline:
Against newer add-on paradigms:
For NeuroWiki treatment ranking purposes, rasagiline remains a moderate-evidence intervention with high actionability in PD symptom management and low confidence for modifying CBS/PSP progression.
In patients with executive dysfunction, fluctuating attention, or early hallucinosis risk, medication changes should be slower than in trial populations. Rasagiline itself is often tolerated, but cumulative neuropsychiatric burden usually reflects the whole regimen (dopamine agonists, anticholinergics, sedatives, antidepressants), not a single drug in isolation.[@us2017][@chen2007] For CBS/PSP clinics, the practical question is frequently whether rasagiline adds enough functional value to justify one more agent in a fragile stack.
Orthostatic symptoms are common in advanced parkinsonian disorders and can worsen with multidrug regimens. Rasagiline is not a dominant driver of hypotension in most cases, but adding it to levodopa or antihypertensive-heavy regimens can shift balance in susceptible patients. Structured standing blood pressure checks and falls surveillance are therefore more useful than relying on symptom self-report alone.[@rascol2005][@parkinson2005][@boxer2022]
Because rasagiline is hepatically metabolized with CYP1A2 relevance, periodic medication review is not optional in long-term care. Exposure can change after seemingly unrelated prescribing decisions (for example antimicrobial changes), smoking cessation, or acute hospitalization. A medication "time-out" at each transition point reduces preventable adverse events in real-world care pathways.[@us2017][@chen2007]
Beyond TEMPO/PRESTO/LARGO/ADAGIO, several randomized datasets improve confidence in rasagiline's symptomatic class effect across treatment contexts. A placebo-controlled adjunct trial in patients already receiving dopamine agonists showed additional motor benefit, supporting use before levodopa-intensification in selected patients.[@barone2014] Regional phase 3 studies in Japan and China reproduced efficacy and acceptable tolerability in early or fluctuating PD populations, improving external validity across prescribing environments.[@hattori2019][@zhang2018]
These trials are clinically important for two reasons. First, they reduce overreliance on a single delayed-start narrative by showing consistent symptomatic improvement across multiple designs and geographies. Second, they better approximate real-world sequencing, where rasagiline is often introduced at transition points between monotherapy and combination regimens rather than as an isolated first-line decision.
Multiple meta-analyses report modest but consistent motor benefit versus placebo in early PD and as adjunct therapy, with acceptable discontinuation and adverse-event profiles in most cohorts.[@abbruzzese2013][@liu2017][@ma2022][@khan2024] This convergent evidence supports rasagiline as an evidence-based symptomatic option in PD care pathways, especially when clinicians prioritize once-daily administration and low regimen complexity.
At the same time, pooled analyses do not resolve the central disease-modification controversy because they aggregate predominantly symptomatic endpoints, and delayed-start inferences remain design-sensitive. For NeuroWiki ranking, the strongest defensible statement remains: symptomatic efficacy is replicated; neuroprotective/disease-modifying efficacy is not definitively established at population level.
Long-term observational analyses suggest rasagiline can remain clinically useful over extended treatment horizons, but interpretation is constrained by confounding from background regimen changes and survivor bias.[@rascol2016] In practical terms, this supports periodic reassessment rather than indefinite continuation by inertia. If functional targets are no longer met, deprescribing or strategy pivoting is appropriate.
Earlier medicinal chemistry and pharmacology work established rasagiline as a potent, selective MAO-B inhibitor with durable target engagement.[@youdim1998][@youdim2001] Primate work showed that selective MAO-B inhibition can amplify striatal dopamine production from levodopa, aligning with the clinical add-on rationale in fluctuating PD.[@baram1998]
In toxin and proteostasis injury models, rasagiline and related compounds demonstrated neuronal preservation signals, including attenuation of dopaminergic injury and improved cellular stress resilience.[@maruyama2005][@soler2008] Additional experiments with the primary metabolite 1-aminoindan reported favorable behavioral, neurochemical, and molecular effects in aging paradigms, supporting the hypothesis that metabolite biology may contribute to non-dopaminergic signaling profiles.[@baram2015]
Mechanistic studies also implicate glutamatergic modulation and direct interactions with aggregation-relevant proteins as potential adjunctive pathways.[@weinreb2011][@weinreb2015] These findings are biologically interesting and justify continued translational research, but they remain insufficient to infer clinically meaningful progression slowing in human tauopathies without dedicated biomarker-driven trials.
For CBS/PSP, the preclinical evidence can be interpreted as stress-pathway support rather than direct tau-target engagement. That distinction should guide trial design:
Dedicated pharmacokinetic studies in Japanese, Chinese, and mixed healthy-volunteer cohorts generally show predictable exposure in standard dosing ranges, while highlighting inter-individual variability related to metabolism and transport biology.[@shinotoh2019][@zhou2016][@bellili2022][@bukhari2022][@zhang2020]
CYP1A2 activity and smoking status can materially shift rasagiline exposure in some cohorts, and transporter polymorphisms may influence PK variability beyond classic metabolic gene effects.[@bellili2022][@bukhari2022] These observations reinforce the need for medication reconciliation and phenotype-aware monitoring at care transitions (hospitalization, smoking cessation, antimicrobial changes).
Routine therapeutic drug monitoring is not standard for rasagiline, but precision-minded practice can still improve safety:
Comparative studies and real-world analyses suggest broadly similar class-level symptomatic efficacy between rasagiline and selegiline, with differences more often seen in tolerability framing, metabolite considerations, and prescribing persistence rather than large efficacy separation.[@cossu2016][@riederer2017][@cossu2016a][@meco2014]
Clinical service data also indicate distinct utilization patterns and resource profiles across MAO-B choices, likely reflecting clinician preference, patient phenotype, and local formulary constraints as much as pharmacology alone.[@cossu2016a]
Most comparative datasets are retrospective and vulnerable to channeling bias. Therefore:
International evidence-based medicine reviews from the Movement Disorder Society continue to place MAO-B inhibitors, including rasagiline, as validated options for motor symptom management with context-dependent strength across disease stages and symptom clusters.[@fox2018][@armstrong2025] This aligns with an implementation model where rasagiline is one component of multimodal care rather than a stand-alone disease-course intervention.
For CBS/PSP programs specifically, guideline extrapolation should remain conservative because direct trial data are sparse and mostly negative for progression impact in PSP.[@stamelou2017] The practical role is targeted symptomatic support under explicit stop rules.
Use rasagiline only when the dominant problem includes a plausible dopaminergic-responsive component (bradykinesia/rigidity overlap), not when axial instability, gaze palsy progression, or cortical/apraxic features dominate from baseline.[@stamelou2017][@boxer2022]
Before initiation, document:
Exclude or defer when interaction control is weak or recent delirium/falls make incremental pharmacologic risk unacceptable.
Run a 4-8 week trial with one or two predefined outcomes:
Stop promptly if targets are not met or adverse-risk balance deteriorates.
If continued, embed rasagiline in a broader bundle:
This keeps therapeutic expectations realistic: incremental symptomatic benefit in selected patients, not disease reversal.
Even after substantial literature expansion, several evidence constraints remain central to interpretation. First, most high-certainty rasagiline data come from Parkinson's disease motor endpoints, not tau-primary syndromes. Second, delayed-start frameworks can generate divergent conclusions depending on model assumptions and subgroup definitions, as illustrated by the persistent ADAGIO 1 mg versus 2 mg asymmetry.[@olanow2009][@olanow2012][@hanagasi2016] Third, real-world comparative analyses versus selegiline are informative but largely non-randomized and susceptible to prescription-channeling and confounding by indication.[@cossu2016][@riederer2017][@cossu2016a]
For CBS/PSP clinicians and caregivers, this means confidence should be tiered by question:
This confidence framing prevents two recurrent implementation errors:
The practical middle path is disciplined therapeutic trials with explicit goals, stop criteria, and integration into non-pharmacologic care bundles. In systems terms, rasagiline should be treated as a controllable lever within a broader care architecture that includes rehabilitation, caregiver training, fall-risk mitigation, swallowing/communication support, and palliative planning when disease stage requires it.[@fox2018][@armstrong2025]